Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2015-01-13

Clinical Trial Update: Study Adding Multikinase Inhibitor Sorafenib to Existing Endocrine Therapy in Patients With Advanced Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating adding sorafenib to existing endocrine therapy in advanced breast cancer was terminated, with results posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Sorafenib (Sorafenib)

Snippet

Sponsor: Suleiman Massarweh | Conditions: Breast Cancer | Phase 2 | Status: TERMINATED | Results posted: 2015-01-13